Procrit (epoetin alfa) - Dec 1, 2005

December 1, 2005

Audience: Hematology/Oncology, Nephrology and other healthcare professionals

[Posted 12/01/2005] Amgen, Ortho Biotech and FDA notified healthcare professionals of revision to the WARNINGS, PRECAUTIONS, ADVERSE REACTIONS, and DOSAGE AND ADMINISTRATION sections of the prescribing information for Epogen and Procrit. The revised labeling provides updated safety information on reports of pure red cell aplasia and severe anemia, with or without other cytopenias, associated with neutralizing antibodies to erythropoietin in patients treated with these products. This has been reported predominantly in patients with CRF receiving these products by subcutaneous administration. Recommendations for evaluation and treatment are provided in the new prescribing information.

[November 2005 - Epogen Letter - Amgen]
[November 2005 - Procrit Letter - Ortho Biotech]

View comments

Hide
(web2)